SCHEMBL770479

SCHEMBL770479

CC(C)c1ccc(CNc2ccc3c(c2)ncn3-c2ccc(-c3ccccc3)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 14/20 0.64
NPC1 O15118 14/20 0.64
POLB P06746 1/20 0.64
KDM4E B2RXH2 11/20 0.63
ALDH1A1 P00352 9/20 0.63
MAPT P10636 8/20 0.63
HPGD P15428 7/20 0.63
SMN1; SMN2 Q16637 6/20 0.63
TDP1 Q9NUW8 5/20 0.63
HTT P42858 3/20 0.63
MEN1 O00255 1/20 0.63
MAPK1 P28482 1/20 0.63
KMT2A Q03164 1/20 0.63
NPSR1 Q6W5P4 1/20 0.63
KIT P10721 2/20 0.59
FLT3 P36888 2/20 0.59
GAA P10253 6/20 0.53
GFER P55789 2/20 0.53
LMNA P02545 6/20 0.53
CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769588 0.92 RAB9A (0.60) RAB9ANPC1POLBKDM4EALDH1A1
SCHEMBL769843 0.92 RAB9A (0.64) RAB9ANPC1POLBKDM4EALDH1A1
SCHEMBL770705 0.92 RAB9A (0.64) RAB9ANPC1POLBKDM4EALDH1A1
SCHEMBL769963 0.89 RAB9A (0.61) RAB9ANPC1POLBKDM4EALDH1A1
SCHEMBL769029 0.88 RAB9A (0.68) RAB9ANPC1POLBKDM4EALDH1A1
SCHEMBL769677 0.86 RAB9A (0.65) RAB9ANPC1POLBKDM4EALDH1A1
SCHEMBL769327 0.86 RAB9A (0.57) RAB9ANPC1POLBKDM4EALDH1A1
SCHEMBL769341 0.85 MAPT (0.70) RAB9ANPC1KDM4EALDH1A1MAPT
SCHEMBL770154 0.85 RAB9A (0.64) RAB9ANPC1POLBKDM4EALDH1A1
SCHEMBL769761 0.85 NPC1 (0.64) RAB9ANPC1POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US claimed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US claimed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection ZC3HAV1, GZMB, GTF3C3 RAB9A 3973/4885NPC1 337/4885POLB 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.